Benefits of Neoadjuvant Chemotherapy in NSCLC-Reference-Cited by-同舟云学术

Benefits of Neoadjuvant Chemotherapy in NSCLC

Published:1996-05 Issue:5 Volume:109 Page:96S-101S
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Pastorino Ugo

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference32 articles.

1. A new international staging system for lung cancer.;Mountain;Chest,1986

2. Prognosis and survival in resected lung carcinoma based on the new international staging system.;Naruke;J Thorac Cardiovasc Surg,1988

3. Surgical treatment for higher-stage non-small cell lung cancer.;Van Raemdonck;Ann Thorac Surg,1992

4. The significance of cytologically negative pleural effusion in bronchogenic carcinoma.;Decker;Chest,1978

5. Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-2627.2) for radically resected bronchogenic carcinoma.;Brunner;Cancer Chemother Rep,1973

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy;Scientific Reports;2018-03-02

2. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection;Interactive CardioVascular and Thoracic Surgery;2014-05-13

3. Tumours;Pathology of the Lungs;2011

4. Non-small cell lung cancer: early stages;Annals of Oncology;2006-04

5. Docetaxel as neoadjuvant therapy for radically treatablestage III non-small-cell lung cancer: a multinational randomised phase III study;Annals of Oncology;2003-01